MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States.
Flawless balance sheet with limited growth.
Share Price & News
How has MacroGenics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: M55 has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: M55 underperformed the German Biotechs industry which returned 6.2% over the past year.
Return vs Market: M55 underperformed the German Market which returned 15% over the past year.
Price Volatility Vs. Market
How volatile is MacroGenics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is MacroGenics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: M55 (€9.25) is trading above our estimate of fair value (€4.55)
Significantly Below Fair Value: M55 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: M55 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: M55 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate M55's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: M55 is good value based on its PB Ratio (1.9x) compared to the DE Biotechs industry average (3.5x).
How is MacroGenics forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: M55 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: M55 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: M55 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: M55's revenue (34.9% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: M55's revenue (34.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: M55 is forecast to be unprofitable in 3 years.
How has MacroGenics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: M55 is currently unprofitable.
Growing Profit Margin: M55 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: M55 is unprofitable, and losses have increased over the past 5 years at a rate of -38.9% per year.
Accelerating Growth: Unable to compare M55's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: M55 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: M55 has a negative Return on Equity (-65.07%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is MacroGenics's financial position?
Financial Position Analysis
Short Term Liabilities: M55's short term assets ($276.2M) exceed its short term liabilities ($57.6M).
Long Term Liabilities: M55's short term assets ($276.2M) exceed its long term liabilities ($38.6M).
Debt to Equity History and Analysis
Debt Level: M55 is debt free.
Reducing Debt: M55 has not had any debt for past 5 years.
Inventory Level: M55 has a high level of physical assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if M55's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: M55 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: M55 has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of -36.9% each year.
What is MacroGenics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate M55's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate M55's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if M55's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if M55's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of M55's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Scott Koenig (67yo)
Dr. Scott Koenig, M.D., Ph.D., has been the President and Chief Executive Officer of Macrogenics, Inc. since September 2001. Dr. Koenig served as Senior Vice President of Research at MedImmune Inc., where ...
CEO Compensation Analysis
Compensation vs Market: Scott's total compensation ($USD5.21M) is above average for companies of similar size in the German market ($USD801.26K).
Compensation vs Earnings: Scott's compensation has increased whilst the company is unprofitable.
|CEO, President & Director||18.4yrs||US$5.21m||2.21% $10.2m|
|Senior VP||11.8yrs||US$1.88m||0.30% $1.4m|
|Senior VP of Research & Chief Scientific Officer||3.4yrs||US$1.93m||0.31% $1.4m|
|Senior VP of Business Development & Portfolio Management and Chief Business Officer||3.4yrs||US$1.88m||0.066% $304.5k|
|Senior VP of Clinical Development & Chief Medical Officer||6.5yrs||US$1.98m||0.039% $177.5k|
|Vice President of Investor Relations & Corporate Communications||0yrs||no data||no data|
|VP & General Counsel||2.7yrs||no data||0.00041% $1.9k|
|Senior Vice President of BioPharmaceutical Development & Manufacturing||0yrs||no data||no data|
|VP, Controller & Treasurer||16.3yrs||no data||no data|
Experienced Management: M55's management team is seasoned and experienced (6.5 years average tenure).
|CEO, President & Director||18.4yrs||US$5.21m||2.21% $10.2m|
|Independent Director||6.4yrs||US$189.07k||no data|
|Independent Director||15.3yrs||US$187.44k||0.037% $169.5k|
|Independent Director||11.6yrs||US$206.32k||0.096% $439.6k|
|Independent Director||5.9yrs||US$204.32k||0.015% $69.6k|
|Independent Director||3.1yrs||US$192.69k||no data|
|Independent Director||2.3yrs||US$178.32k||no data|
|Independent Director||3.1yrs||US$189.07k||no data|
Experienced Board: M55's board of directors are considered experienced (6.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.4%.
MacroGenics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: MacroGenics, Inc.
- Ticker: M55
- Exchange: DB
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$497.415m
- Listing Market Cap: US$459.114m
- Shares outstanding: 48.96m
- Website: https://www.macrogenics.com
Number of Employees
- MacroGenics, Inc.
- 9704 Medical Center Drive
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MGNX||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Oct 2013|
|M55||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Oct 2013|
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3; MGA012, an anti-PD-1 monoclonal antibody, which inhibits programmed cell death protein 1 (PD-1); MGD013, a monoclonal antibody that targets the immune checkpoints PD-1 and lymphocyte-activation gene 3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company is developing MGD009, a DART molecule that targets B7-H3 expressed on tumor cells and CD3; MGC018, an antibody drug conjugate, which targets solid tumors expressing B7-H3; and MGD007, a DART molecule, which targets glycoprotein A33 and CD3; and MGD014, a DART molecule that targets virus-infected cells. It has strategic collaborations with Incyte Corporation; Les Laboratoires Servier and Institut de Recherches Servier; and Zai Lab Limited. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/17 22:10|
|End of Day Share Price||2020/02/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.